Results: 8
Belimumab Efficacy is 'Mild' but Market Potential Still Great.
- Published in:
- BioDrugs, 2011, v. 25, n. 3, p. 203, doi. 10.2165/11591850-000000000-00000
- By:
- Publication type:
- Article
Hot Ortho-Biologic Topics at AAOS 2011.
- Published in:
- BioDrugs, 2011, v. 25, n. 3, p. 197, doi. 10.2165/11592710-000000000-00000
- By:
- Publication type:
- Article
Temsirolimus in Relapsed and/or Refractory Mantle Cell Lymphoma.
- Published in:
- BioDrugs, 2011, v. 25, n. 3, p. 193, doi. 10.2165/11207050-000000000-00000
- By:
- Publication type:
- Article
Imatinib: As Adjuvant Therapy for Gastrointestinal Stromal Tumor.
- Published in:
- BioDrugs, 2011, v. 25, n. 3, p. 191, doi. 10.2165/11207040-000000000-00000
- By:
- Publication type:
- Article
Neovascular Age-Related Macular Degeneration.
- Published in:
- BioDrugs, 2011, v. 25, n. 3, p. 171, doi. 10.2165/11589330-000000000-00000
- By:
- Publication type:
- Article
Bevacizumab-Induced Hypertension.
- Published in:
- BioDrugs, 2011, v. 25, n. 3, p. 159, doi. 10.2165/11590180-000000000-00000
- By:
- Publication type:
- Article
Activity and Safety of Dasatinib as Second-Line Treatment or in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Patients.
- Published in:
- BioDrugs, 2011, v. 25, n. 3, p. 147, doi. 10.2165/11591840-000000000-00000
- By:
- Publication type:
- Article
Erlotinib.
- Published in:
- BioDrugs, 2011, v. 25, n. 3, p. 139, doi. 10.2165/11206910-000000000-00000
- By:
- Publication type:
- Article